MiMedx Group Past Earnings Performance
Past criteria checks 3/6
MiMedx Group has been growing earnings at an average annual rate of 42.2%, while the Biotechs industry saw earnings growing at 15% annually. Revenues have been declining at an average rate of 0.3% per year. MiMedx Group's return on equity is 50.4%, and it has net margins of 20.5%.
Key information
42.2%
Earnings growth rate
41.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -0.3% |
Return on equity | 50.4% |
Net Margin | 20.5% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry
May 21We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
May 14Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet
Mar 27We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
Jan 05MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Dec 18Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?
Aug 08Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?
Apr 22Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?
Dec 20MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX
Sep 12MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range
Sep 06Is MiMedx Group (NASDAQ:MDXG) Using Too Much Debt?
Apr 12Is MiMedx Group (NASDAQ:MDXG) A Risky Investment?
Nov 30Revenue & Expenses Breakdown
How MiMedx Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 335 | 68 | 216 | 12 |
31 Dec 23 | 321 | 56 | 216 | 13 |
30 Sep 23 | 309 | 11 | 215 | 8 |
30 Jun 23 | 295 | -6 | 219 | 11 |
31 Mar 23 | 281 | -18 | 225 | 10 |
31 Dec 22 | 268 | -27 | 221 | 13 |
30 Sep 22 | 261 | -34 | 216 | 22 |
30 Jun 22 | 256 | -28 | 209 | 20 |
31 Mar 22 | 258 | -19 | 202 | 19 |
31 Dec 21 | 242 | -18 | 199 | 10 |
30 Sep 21 | 260 | -35 | 223 | 16 |
30 Jun 21 | 261 | -83 | 233 | 15 |
31 Mar 21 | 246 | -88 | 231 | 13 |
31 Dec 20 | 248 | -83 | 240 | 12 |
30 Sep 20 | 256 | -73 | 212 | 11 |
30 Jun 20 | 281 | -8 | 210 | 10 |
31 Mar 20 | 294 | -17 | 233 | 11 |
31 Dec 19 | 299 | -26 | 265 | 11 |
30 Sep 19 | 315 | -54 | 270 | 13 |
30 Jun 19 | 314 | -67 | 287 | 14 |
31 Mar 19 | 342 | -48 | 295 | 15 |
31 Dec 18 | 359 | -30 | 295 | 16 |
30 Sep 18 | 354 | 41 | 275 | 15 |
30 Jun 18 | 352 | 59 | 260 | 16 |
31 Mar 18 | 333 | 65 | 235 | 17 |
31 Dec 17 | 321 | 65 | 220 | 18 |
30 Sep 17 | 303 | 35 | 216 | 18 |
30 Jun 17 | 283 | 21 | 205 | 15 |
31 Mar 17 | 264 | 15 | 192 | 14 |
31 Dec 16 | 222 | 0 | 172 | 14 |
30 Sep 16 | 227 | 20 | 168 | 11 |
30 Jun 16 | 212 | 23 | 154 | 10 |
31 Mar 16 | 200 | 27 | 144 | 9 |
31 Dec 15 | 187 | 29 | 133 | 8 |
30 Sep 15 | 175 | 20 | 126 | 8 |
30 Jun 15 | 160 | 17 | 115 | 8 |
31 Mar 15 | 139 | 11 | 104 | 7 |
31 Dec 14 | 118 | 6 | 90 | 7 |
30 Sep 14 | 97 | 1 | 75 | 7 |
30 Jun 14 | 79 | -3 | 64 | 6 |
31 Mar 14 | 67 | -3 | 54 | 5 |
31 Dec 13 | 59 | -4 | 46 | 5 |
30 Sep 13 | 52 | -4 | 40 | 5 |
30 Jun 13 | 44 | -8 | 33 | 4 |
Quality Earnings: MDXG has a high level of non-cash earnings.
Growing Profit Margin: MDXG became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MDXG has become profitable over the past 5 years, growing earnings by 42.2% per year.
Accelerating Growth: MDXG has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MDXG has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: MDXG's Return on Equity (50.4%) is considered outstanding.